CD34 as a potential prognostic indicator for camrelizumab response in advanced non-small-cell lung cancer: insights from digital spatial profiling.

ABSTRACT:

Background

Given that only a small subset of patients with advanced non-small-cell lung cancer (aNSCLC) benefit from immune checkpoint inhibitors (ICIs), the effectiveness of ICIs is often compromised by the complex interplay within the tumor microenvironment (TME).

Objectives

To identify predictive biomarkers associated with ICI resistance at a multi-omics spatial level.

Design

A total of eight aNSCLC patients who received first-line anti-programmed cell death protein-1 (PD-1) monoclonal antibody camrelizumab at Shandong Cancer Hospital and Institute between 2021 and 2022 were included in the discovery cohort. An additional validation cohort of 45 samples from camrelizumab-treated aNSCLC patients was also enrolled.

Methods

NanoString GeoMx^® digital

SUBMITTER: Huang X 

PROVIDER: S-EPMC11489950 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature